Affiliation:
1. Department of Pharmaceutical Analysis, ISF College of Pharmacy, Ghal Kalan, G.T Road, Moga, Punjab, 142001, India
Abstract
Background:
Renal cell carcinoma (RCC) is a diverse collection of malignancies with varying histological
characteristics, molecular changes, prognosis, and therapeutic response. Tivozanib was first approved in March 2021
by USFDA with the brand name Fotivda. Tivozanib hydrochloride monohydrate is an oral medication that is used to
treat relapsed or refractory renal cell carcinoma.
Objective:
In this review, we explain renal cell carcinoma and its different types of treatment by the anti-renal carcinoma
drugs.
Methods:
A comprehensive literature search was conducted in the relevant databases, like ScienceDirect, PubMed,
ResearchGate, and Google Scholar, to identify the studies.
Conclusion:
Tivozanib is an oral VEGFR-1, VEGFR-2, and VEGFR-3 tyrosine kinase inhibitor that is extremely
selective and powerful. It has much less affinity for other receptor tyrosine kinases than multi-targeted TKIs now in
clinical use. Because of its long half-life in circulation, it may be able to block VEGFRs more consistently. Doserelated
controllable hypertension is its most commonly seen drug-related side event. Fatigue, hoarseness, and diarrhea,
which are all common side effects, are not dose-related. Because of its target specificity, tivozanib can work well with
other medications that have low side effects. Blocking both the VEGF and mTOR signaling pathways at the same time
provides the benefit of synergistic antitumor efficacy while also preventing treatment resistance. Thus, overall we can
say that the drug tivozanib is suitable for treatment in patients with renal cell carcinoma and can be investigated in
multi-center clinical trials.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献